ALS, which is also known as Lou Gehrig’s Disease, is a rare neurological disease that affects motor neurons — the nerve cells. Why are so many amyotrophic lateral sclerosis (ALS) drug trials are ...

A promising clinical signal of a novel biologic combination immunotherapy in Amyotrophic Lateral Sclerosis (ALS) has been announced following the publication of a peer-reviewed study. ALS, also known ...

Some blood lipid biomarkers linked to cardiovascular disease risk are also associated with a lower risk of amyotrophic lateral sclerosis (ALS) suggest the findings of a large epidemiology study ...

Some blood lipid biomarkers linked to cardiovascular disease risk are also associated with a lower risk of amyotrophic lateral sclerosis (ALS) suggest the findings of a large epidemiology study ...

Using the gene scissors CRISPR and stem cells, researchers at Stockholm University and the UK Dementia Research Institute (UK DRI) at King’s College London have managed to identify a common ...

A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of Neuroinflammation that, for the first time, examines in depth the role of the ...

Charcot described amyotrophic lateral sclerosis (ALS) in 1874. Despite progress, this creeping paralysis, known colloquially as Lou Gehrig's disease, is still not visibly affected by available ...

Despite modern imaging and genetic testing, diagnosing amyotrophic lateral sclerosis (ALS) remains challenging, particularly when distinguishing it from clinically similar neurodegenerative disorders.

Dr. Michael Strong, Arthur J. Hudson Chair in ALS Research at Western’s Schulich School of Medicine & Dentistry, has discovered a protein that could lead to a treatment for ALS. In a groundbreaking ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Amylyx pulled its ALS drug from ...